Pharmaceutical companies are scrambling to deploy CDK4/6 inhibitors, and market competition is becoming more intense

A few days ago, Eli Lilly announced in Shanghai that its CDK4/6 inhibitor Abeccil (trade name: Weizhe) was officially launched in China for early breast cancer indications
.
It is reported that the drug is also the first CDK4/6 inhibitor approved in China for patients with early breast cancer
.
Data show that CDK4/6, cyclin-dependent kinases 4 and 6, is a key conditional protein in the human cell division and proliferation cycle, which can trigger the transition of the cell cycle from the growth phase to the DNA replication phase
.
CDK4/6 is overactive in many malignant tumors, especially in hormone receptor (HR)-positive breast cancer, showing significant activity, promoting cancer cell proliferation and spreading, while CDK4/6 inhibitors can block cell cycle in growth phase , thereby inhibiting tumor cell proliferation
.
At present, CDK4/6 inhibitors have become popular target drugs in the field of tumor therapy
.
At present, many companies are in the layout and development
.
In China, in August 2018, Pfizer's palbociclib was approved, becoming the first CDK4/6 inhibitor to be marketed in China
.
In March 2021, Eli Lilly Abecili for advanced breast cancer indications was launched in China, which is another CDK4/6 inhibitor approved for marketing in China
.
In addition to the above companies, as of February 2020, there are a total of 21 CDK4/6 inhibitors in clinical development worldwide, 11 of which belong to China's Class 1 new drugs, and Hengrui is making rapid progress
.
It is understood that in March 2021, the original CDK4/6 inhibitor isethionate Dalsili tablets (trade name: Erlikang) Dalsili, independently developed by Hengrui Medicine, was approved by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration.
Include breakthrough therapies
.
In April of the same year, it was included in the priority review and approval list again
.
On December 31, 2021, Dalsili was officially approved by the National Medical Products Administration (NMPA) for listing in China
.
Approved indications: Combined with fulvestrant for the treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) recurrent or metastatic breast cancer who have progressed after previous endocrine therapy
.
It is worth mentioning that this year, the Dalsili tablets (trade name: Erlikang) independently developed by Hengrui Medicine have been prescribed in Jilin Cancer Hospital
.
In addition, experts from Shanghai, Guangzhou, Hangzhou, Nanjing, Tianjin, Harbin, Shenyang, Qingdao, Changsha, Nanchang, Chongqing, Xi'an, Wuhan, Zhengzhou, Fuzhou and other places have also successively issued local first-day prescriptions
.
Up to now, Dalsili has been shipped to all parts of the country, more than 250 cities in 26 provinces across the country, and more than 1,000 pharmacies have arrived
.
In general, the domestic tumor market has huge potential, so many domestic pharmaceutical companies are involved in CDK4/6 inhibitors
.
At the same time, major pharmaceutical companies have begun to make more and more new progress in the research and clinical application of CDK4/6 inhibitors.
It is believed that CDK4/6 inhibitors will be more widely used in the near future.
The application can not only benefit more tumor patients, but also create huge economic benefits
.
However, in this context, it should be noted that there are currently more than 20 domestic pharmaceutical companies deploying CDK4/6 inhibitors, so the industry expects that the market competition pattern in the future may also be quite fierce
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.